| Madeleine Verdolino, | |
|
24 Park St, Attleboro, MA 02703-2338 | |
| (508) 222-0089 | |
| Not Available |
| Full Name | Madeleine Verdolino |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Psychiatric/mental Health |
| Location | 24 Park St, Attleboro, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538800123 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | RN2351131 (Massachusetts) | Primary |
| 163W00000X | Registered Nurse | RN2351131 (Massachusetts) | Secondary |
| Entity Name | New England Center For Psychiatric And Addiction Disorders Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154713030 PECOS PAC ID: 7911213764 Enrollment ID: O20150825004022 |
News Archive
In a step towards a possible treatment for Huntington's disease, scientists at Albert Einstein College of Medicine of Yeshiva University have shown for the first time that the accumulation of a mutated protein may explain damaging cellular behavior in Huntington's disease. Their research is described in the April 11 online edition of Nature Neuroscience.
Preliminary results from the world's largest sleep study have shown that people who sleep on average between 7 to 8 hours per night performed better cognitively than those who slept less, or more, than this amount.
The Vatican on Thursday announced it "will host an international conference in May on preventing [HIV/AIDS] and caring for those afflicted with it amid continued confusion over its position concerning condoms as a way to prevent HIV transmission," the Associated Press reports.
Akorn, Inc., a niche generic pharmaceutical company, today announced that it has acquired the NDA and all rights to Betimol (timolol ophthalmic solution) 0.25% & 0.5% from Santen. Akorn plans to begin shipping Betimol in the first quarter of 2014.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United States patent (No. 8,314,100), titled "1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives."
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Madeleine Verdolino, 24 Park St, Attleboro, MA 02703-2338 Ph: (508) 222-0089 | Madeleine Verdolino, 24 Park St, Attleboro, MA 02703-2338 Ph: (508) 222-0089 |
News Archive
In a step towards a possible treatment for Huntington's disease, scientists at Albert Einstein College of Medicine of Yeshiva University have shown for the first time that the accumulation of a mutated protein may explain damaging cellular behavior in Huntington's disease. Their research is described in the April 11 online edition of Nature Neuroscience.
Preliminary results from the world's largest sleep study have shown that people who sleep on average between 7 to 8 hours per night performed better cognitively than those who slept less, or more, than this amount.
The Vatican on Thursday announced it "will host an international conference in May on preventing [HIV/AIDS] and caring for those afflicted with it amid continued confusion over its position concerning condoms as a way to prevent HIV transmission," the Associated Press reports.
Akorn, Inc., a niche generic pharmaceutical company, today announced that it has acquired the NDA and all rights to Betimol (timolol ophthalmic solution) 0.25% & 0.5% from Santen. Akorn plans to begin shipping Betimol in the first quarter of 2014.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United States patent (No. 8,314,100), titled "1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives."
› Verified 5 days ago
Kerri Ann Fenore, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 228 Washington St Ste 280b, Attleboro, MA 02703 Phone: 774-282-7002 | |
Darcy P. Renaghan, N.P. Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 550 N Main St, Ste 3, Attleboro, MA 02703 Phone: 508-543-8595 Fax: 508-698-5373 | |
Stephanie G. Williams, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 687 N Main St, Attleboro, MA 02703 Phone: 508-222-3200 Fax: 508-342-1903 | |
Mrs. Leanne Palmer Nygaard Szwaja, ACNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 211 Park St, Attleboro, MA 02703 Phone: 508-222-5200 | |
Stephanie Frycki, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 159 Pleasant St, Attleboro, MA 02703 Phone: 508-223-2474 Fax: 508-342-1922 | |
Elizabeth Rogers, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 303 N Main St, Attleboro, MA 02703 Phone: 508-222-2086 | |
Tina M Rose, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 550 N Main St, Suite 3, Attleboro, MA 02703 Phone: 508-699-7800 Fax: 508-699-7801 |